perillaldehyde has been researched along with Hyperlipemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Deng, W; Firempong, CK; Omari-Siaw, E; Peng, W; Wang, H; Wang, YW; Xu, X; Yu, J; Zhu, Y | 1 |
| Agyare, R; Cao, X; Firempong, CK; Gu, Z; Omari-Siaw, E; Sun, C; Wang, Q; Xu, X; Yu, J; Zhu, Y | 1 |
2 other study(ies) available for perillaldehyde and Hyperlipemia
| Article | Year |
|---|---|
Hypolipidemic potential of perillaldehyde-loaded self-nanoemulsifying delivery system in high-fat diet induced hyperlipidemic mice: Formulation, in vitro and in vivo evaluation.
Topics: Administration, Oral; Animals; Biological Availability; Chemistry, Pharmaceutical; Cholesterol; Diet, High-Fat; Drug Carriers; Drug Delivery Systems; Emulsions; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Mice; Monoterpenes; Nanoparticles; Particle Size; Rats; Rats, Sprague-Dawley; Solubility; Surface-Active Agents; Triglycerides | 2016 |
Tissue distribution and enhanced in vivo anti-hyperlipidemic-antioxidant effects of perillaldehyde-loaded liposomal nanoformulation against Poloxamer 407-induced hyperlipidemia.
Topics: Administration, Oral; Animals; Antioxidants; Area Under Curve; Biological Availability; Drug Delivery Systems; Half-Life; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liposomes; Male; Mice; Monoterpenes; Nanoparticles; Poloxamer; Rats; Rats, Sprague-Dawley; Solubility; Superoxide Dismutase; Tissue Distribution | 2016 |